Company intelligence / Profile preview

Oncologie

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Oncologie is running clinical trials in advanced, treatment-resistant cancers using investigational agents bavituximab and navicixizumab, both with immune-modulating or anti-angiogenic mechanisms, guided by their proprietary RNA-based biomarker platform. Interim Phase 1/2 data in ovarian and gastric cancers have shown promising response rates and manageable toxicity, though pivotal results are pending.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Oncologie.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncologie.

Explore the full profile